A Chip Stock Gets Checked - Behind the Drop in Intel; and Gilead’s Remdesivir Gets the Green Light
CNBC
Intel shares plunged after the company reported weak results for its data center group. What’s next for the stock that’s been far underperforming the rest of the semi sector. And Gilead gets FDA approval for remdesivir. We break down the rest of the race for a COVID vaccine.